PubHawk
Orphanet J Rare Dis March 2016 PMID 26939863

Orphan devices: yesterday is history; tomorrow is mystery: towards a European orphan device directive?

Marc M Dooms

Full text PDF Download social card

Mentions

4
Peak: 1 in Nov 2021
across 3 sources since Nov 2021

Extended reach

144
potential audience

Total likes

0

Video views

11

Mentions per month

Nov 2021 – Sep 2025

Where it's discussed

  • X / Twitter2 posts
  • YouTube1 videos
  • News1 articles

AI synopsis

What people are saying

Discussions reflect a shared understanding of the regulatory gaps for orphan devices in Europe, with mentions of the US's Humanitarian Use Device exemption as a benchmark. The tone remains informational and optimistic about policy development, using phrases like 'crucial need' and 'support for regulations' to highlight the importance and potential impact of the publication.

AgreementModerate agreement

Most discussions acknowledge the importance of establishing regulatory frameworks for orphan devices, showing general agreement with the article’s call for stronger policies.

InterestModerate interest

Participants exhibit a moderate interest, often highlighting the need for innovation and safety in rare disease treatments, but not expressing highly personal or emotional reactions.

EngagementModerate engagement

Comments include references to ongoing regulatory issues and potential policy impacts, indicating a reasonable level of engagement without detailed debate.

ImpactModerate impact

The conversations suggest that the article's insights could influence policy considerations and stimulate further discussions about device regulation in Europe.

Abstract in brief

  • The text discusses the lack of specific regulations and incentives for developing "orphan devices," which are medical devices needed for treating rare conditions, similar to orphan drugs, with Europe currently lacking a comprehensive framework.
  • A public consultation in Europe shows support for establishing an orphan device directive, but unlike the US, which has a Humanitarian Use Device exemption, Europe has yet to implement such policies, highlighting the need for regulatory stimulation.
  • Ongoing postmarketing surveillance, including materiovigilance and patient-reported outcomes, is crucial for ensuring safety and effectiveness, especially given the shorter marketing periods for devices, and incentives are necessary to promote R&D in this niche area, especially when surgical intervention is the only treatment option.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Marc Dooms
@DoomsMarc · X

@irdirc https://t.co/BVnqj6WVS2

Dec 12, 2021 · 62 followers View post →
Marc Dooms
@DoomsMarc · X

@eurordis @irdirc https://t.co/BVnqj6WVS2

Nov 22, 2021 · 62 followers View post →

All mentions

Marc Dooms
@DoomsMarc · X

@irdirc https://t.co/BVnqj6WVS2

Dec 12, 2021 · 62 followers View post →
Marc Dooms
@DoomsMarc · X

@eurordis @irdirc https://t.co/BVnqj6WVS2

Nov 22, 2021 · 62 followers View post →
A Comparative Study of Medical Device Regulation Between ...
News

Available from: https://link.springer.com/article/10.1186/ Health. 2021;3(3):e195–e203. doi: 10.1016/S2589-7500(20)30292-2 s13023-016-0393-3

Sep 22, 2025 View →